Figure 4
From: Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin
ERK inhibited tumors in a mouse xenograft model show enhanced sensitivity to Dox. HMESO cells (5 × 106) stably transfected with shERK1, skERK2, or shControl (shCon) constructs were injected subcutaneously at 4 dorsal sites on SCID mice. Eight days after cell injections, localized Dox or saline injections (6 μg/50 μl/tumor, 3 times a wk for 6 wks) were started (shown by arrow heads). At autopsy, tumors were harvested and volumes were calculated as described in 'Materials and Methods'. N = 3 mice/group, or 12 tumors/group. Statistical analysis (see Materials and Methods) performed showed that Dox-treated mice in the shERK1 or shERK2 groups had significantly slower tumor growth than the Dox-treated mice in the shControl group. All conclusions were derived by statistical analysis (described in the Method section) performed on different groups to compare alteration in tumor growth rate and not tumor volume.